ArticleCancer immunology, immunotherapy : CII2019
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy.
Article in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Advances inMolecular therapy. Nucleic acids · 2026Review
- Review
- Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer.Breast cancer research : BCR · 2025Article
- TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges.Journal of translational medicine · 2024Review
- Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.Journal for immunotherapy of cancer · 2023Article
- RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Review
- A computational algorithm to assess the physiochemical determinants of T cell receptor dissociation kinetics.Computational and structural biotechnology journal · 2022Article
- Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer.Frontiers in immunology · 2022Review
- A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT).Frontiers in oncology · 2022Article
- Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- CAR T-Cell Production Using Nonviral Approaches.Journal of immunology research · 2021Review
- T-cell receptor affinity in the age of cancer immunotherapy.Molecular carcinogenesis · 2020Review
- Long-term surviving cancer patients as a source of therapeutic TCR.Cancer immunology, immunotherapy : CII · 2020Review
- A bicistronic vector backbone for rapid seamless cloning and chimerization of αβT-cell receptor sequences.PloS one · 2020Article
Corrections and comments
- Retraction · 2019-11-27Error in Image ·
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
Off-target toxicity due to the expression of target antigens in normal tissue or TCR cross-reactivity represents a major risk when using T cell receptor (TCR)-engineered T cells for treatment of solid tumours. Due to the inherent cross-reactivity of TCRs it is difficult to accurately predict their target recognition pre-clinically. It has become evident that direct testing in a human being represents the best evaluation of the risks. There is, therefore, a clear unmet need for assessing the safety of a therapeutic TCR in a more controllable manner than by the injection of permanently modified cellular products. Using transiently modified T cells combined with dose escalation has already been shown feasible for chimeric antigen receptor (CAR)-engineered T cells, but nothing is yet reported for TCR. We performed a preclinical evaluation of a therapeutic TCR transiently expressed in T cells by mRNA electroporation. We analyzed if the construct was active in vitro, how long it was detectable for and if this expression format was adapted to in vivo efficacy assessment. Our data demonstrate the potential of mRNA engineered T cells, although less powerful than permanent redirection, to induce a significant response. Thus, these findings support the development of mRNA based TCR-therapy strategies as a feasible and efficacious method for evaluating TCR safety and efficacy in first-in-man testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.